Free Trial
NASDAQ:MEIP

MEI Pharma Q3 2025 Earnings Report

MEI Pharma logo
$6.74 +0.14 (+2.12%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$6.52 -0.22 (-3.19%)
As of 07/25/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MEI Pharma EPS Results

Actual EPS
-$0.39
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

MEI Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MEI Pharma Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

MEI Pharma's Q4 2025 earnings is scheduled for Wednesday, September 17, 2025, with a conference call scheduled on Tuesday, September 23, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

MEI Pharma Earnings Headlines

MEI Pharma’s Strategic Shift with Litecoin Treasury
HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
See More MEI Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MEI Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MEI Pharma and other key companies, straight to your email.

About MEI Pharma

MEI Pharma (NASDAQ:MEIP), a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

View MEI Pharma Profile

More Earnings Resources from MarketBeat